Kathryn-Ann Stamm Serves as Judge at INTA’s 2025 Saul Lefkowitz Moot Court Competition
February 04, 2025
On February 1, 2025, Cravath of counsel Kathryn‑Ann Stamm participated in the New York regional round of the Saul Lefkowitz Moot Court Competition, hosted by the International Trademark Association. Kathryn‑Ann served as a judge for the event, where she evaluated the oral arguments presented by the participating teams. The competition underscores the importance of nurturing the next generation of legal professionals and tackles important issues arising under U.S. trademark and unfair competition law.
Related Practices & Industries
People
- Photo
-
-
J.D., 2016, Cornell Law School
-
LL.M., 2016, City University of Hong Kong
-
Master II, 2016, University Paris 1 Panthéon-Sorbonne
-
Master I, 2013, University Paris 1 Panthéon-Sorbonne
-
LL.B., 2013, University Paris 1 Panthéon-Sorbonne
-
LL.B., 2013, King's College LondonFirst Class Honors.
- New York
Education
Admitted In
Related News & Insights
Deals & Cases
January 06, 2025
Disney’s Combination of its Hulu + Live TV Business with Fubo
On January 6, 2025, The Walt Disney Company (“Disney”) and FuboTV Inc. (“Fubo) announced that they have entered into a definitive agreement for Disney to combine its Hulu + Live TV business with Fubo, forming a combined virtual MVPD company of which Disney will become the majority owner.
Deals & Cases
December 04, 2024
OMERS Private Equity’s Acquisition of Integris
On December 3, 2024, OMERS Private Equity, which manages investments globally on behalf of OMERS, one of Canada’s largest defined benefit pension plans, announced the signing of a definitive agreement to acquire a majority stake in Integris, a leading provider of IT services in the United States, from Frontenac, a Chicago‑based private equity firm. Financial terms of the transaction were not disclosed. Cravath is representing OMERS Private Equity in connection with the transaction.
Deals & Cases
November 04, 2024
DRI Healthcare Trust’s Acquisition of a Synthetic Royalty Interest in the Worldwide Sales of Sebetralstat and Equity Investment in KalVista Pharmaceuticals
On November 4, 2024, DRI Healthcare Trust (“the Trust”), a global leader in providing financing to advance innovation in the life sciences industry, announced it has acquired a royalty interest in the worldwide net sales of all formulations of sebetralstat, an investigational oral plasma kallikrein inhibitor for the treatment of Hereditary Angioedema, from KalVista Pharmaceuticals ("KalVista") for an aggregate purchase price of up to $179 million, comprised of a $100 million upfront payment, up to $57 million in a sales-based milestone payment and a one-time $22 million optional payment. Additionally, the Trust is making a $5 million investment in KalVista’s common stock in a private placement transaction. Cravath is representing DRI Healthcare Trust in connection with the transaction.
Deals & Cases
October 07, 2024
Vista Outdoor’s $1.125 Billion Sale of Revelyst to SVP
On October 4, 2024, Vista Outdoor Inc. (“Vista Outdoor”), the parent company of more than three dozen renowned brands that design, manufacture and market sporting and outdoor products, announced it has entered into a definitive agreement with funds managed by Strategic Value Partners, LLC, and its affiliates (“SVP”), a global alternative investment firm with approximately $19 billion of assets under management, to sell Revelyst in an all‑cash transaction based on an enterprise value of $1.125 billion. In connection with the SVP Transaction, Vista Outdoor also entered into an amendment to the merger agreement with Czechoslovak Group a.s. (“CSG”) to acquire The Kinetic Group, increasing the purchase price for The Kinetic Group to $2.225 billion. Together, the CSG Transaction and the SVP Transaction represent an enterprise value of $3.35 billion for Vista Outdoor and will deliver an estimated $45 per share in cash to Vista Outdoor stockholders. Cravath is representing Vista Outdoor in connection with the transaction.
